The firm said that in its product pipeline in 2019 it focused on organ transplant and lung health, involving use of its multiplexed research-use TORdx Lung tests.
The test detects 20 common viruses and bacteria that cause upper respiratory infections using the firm's high-throughput, automated MDx-3000 instrument.
The firm moved closer to commercializing its lung transplant test, and it was notified by New York State that it could begin testing patient samples using its DTC celiac disease test.
